Published in Oncogene on September 18, 2008
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A (2009) 3.26
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol (2013) 3.02
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell (2014) 2.09
Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J (2009) 1.88
Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med (2010) 1.84
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int (2015) 1.42
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A (2009) 1.37
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol (2014) 1.32
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr (2015) 1.27
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene (2012) 1.22
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res (2012) 1.19
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet (2012) 1.19
PI3Kα inhibitors that inhibit metastasis. Oncotarget (2010) 1.19
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med (2012) 1.18
Phosphoinositide 3-kinase signaling in the vertebrate retina. J Lipid Res (2010) 1.15
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer (2011) 1.15
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. Proc Natl Acad Sci U S A (2009) 1.13
The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener (2009) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer (2013) 1.11
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci (2014) 1.10
Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol (2010) 1.10
Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Front Oncol (2013) 1.10
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther (2010) 1.08
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book (2013) 1.06
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer (2014) 1.03
14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One (2010) 1.02
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol (2012) 1.01
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget (2013) 1.01
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
Membrane lipids in invadopodia and podosomes: key structures for cancer invasion and metastasis. Oncotarget (2010) 1.00
Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep (2010) 0.99
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol (2012) 0.98
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One (2012) 0.98
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One (2010) 0.97
Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes. Apoptosis (2012) 0.97
PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med (2015) 0.96
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathog (2011) 0.96
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res (2015) 0.96
Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95
Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem (2010) 0.94
Thinking outside the box about Ras. J Biol Chem (2008) 0.93
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev (2012) 0.92
microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci (2014) 0.91
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ (2012) 0.89
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One (2014) 0.89
p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol (2013) 0.89
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Commun Signal (2015) 0.88
New Approaches to Target T-ALL. Front Oncol (2014) 0.88
p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation. Biomed Res Int (2012) 0.88
Membrane environment exerts an important influence on rac-mediated activation of phospholipase Cγ2. Mol Cell Biol (2011) 0.87
Structural effects of oncogenic PI3Kα mutations. Curr Top Microbiol Immunol (2010) 0.87
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol (2012) 0.86
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. J Thorac Oncol (2015) 0.86
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer. Mol Cancer (2015) 0.85
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat (2014) 0.85
A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res (2014) 0.85
Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem (2011) 0.85
Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. Haematologica (2012) 0.85
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS One (2014) 0.85
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int J Mol Sci (2015) 0.85
Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev (2014) 0.84
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med (2014) 0.84
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am J Respir Crit Care Med (2014) 0.84
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (2000) 8.35
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A (1999) 7.70
Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature (1999) 7.66
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell (2004) 6.35
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol (2003) 6.32
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26
PI(3,4,5)P3 and PI(4,5)P2 lipids target proteins with polybasic clusters to the plasma membrane. Science (2006) 6.25
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science (2000) 5.84
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
PTEN: one gene, many syndromes. Hum Mutat (2003) 5.79
Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem (1999) 5.66
Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell (1991) 5.65
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem (1998) 5.01
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol (2002) 4.85
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science (2000) 4.61
Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52
FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol (2003) 4.31
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci (1996) 4.20
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J (1996) 3.99
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (1999) 3.81
PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem (2001) 3.78
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell (2000) 3.68
Oncogenic PI3K and its role in cancer. Curr Opin Oncol (2006) 3.61
A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell (1994) 3.50
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci (2005) 3.45
Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst (1999) 3.41
PTEN: life as a tumor suppressor. Exp Cell Res (2001) 3.41
PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J (1994) 3.39
Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans (2006) 3.37
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res (2005) 3.19
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem (1999) 3.17
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome (2002) 2.79
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature (2004) 2.73
Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol (2002) 2.70
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med (2002) 2.68
Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem (2003) 2.66
Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol (2004) 2.59
Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle (2006) 2.39
Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity (2002) 2.25
Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer (2005) 2.06
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol (2005) 2.04
Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci U S A (1999) 2.04
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol (1999) 1.96
The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol (1994) 1.91
Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci (2007) 1.90
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J (2008) 1.79
Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol (2006) 1.76
Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene (1993) 1.73
Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science (1987) 10.25
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature (1976) 9.81
Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. Cell (1978) 7.46
Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. Cell (1977) 7.23
Fos-associated protein p39 is the product of the jun proto-oncogene. Science (1988) 6.34
Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology (1969) 6.24
Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology (1977) 5.90
Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. Virology (1971) 5.75
Gel electrophoresis of avian leukosis and sarcoma viral RNA in formamide: comparison with other viral and cellular RNA species. J Virol (1973) 5.70
Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun. Proc Natl Acad Sci U S A (1987) 5.06
Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A (1987) 4.96
Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci U S A (1970) 4.91
RNA species obtained from clonal lines of avian sarcoma and from avian leukosis virus. Virology (1973) 4.73
Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. Virology (1973) 4.56
Reciprocal patterns of genetic resistance to avian tumor viruses in two lines of chickens. Virology (1965) 4.27
Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. Proc Natl Acad Sci U S A (1973) 4.19
Glycoprotein components of avian and murine RNA tumor viruses. Virology (1970) 3.92
Characteristics of two new avian tumor virus subgroups. Virology (1969) 3.81
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
An avian leukosis virus related to RSV(O): properties and evidence for helper activity. Virology (1971) 3.68
The RNA of avian acute leukemia virus MC29. Proc Natl Acad Sci U S A (1977) 3.60
Avian tumor virus RNA: a comparison of three sarcoma viruses and their transformation-defective derivatives by oligonucleotide fingerprinting and DNA-RNA hybridization. Proc Natl Acad Sci U S A (1973) 3.46
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A (2000) 3.40
Reversion from transformed to normal phenotype by inhibition of protein synthesis in rat kidney cells infected with a temperature-sensitive mutant of Rous sarcoma virus. Proc Natl Acad Sci U S A (1976) 3.38
The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology (1998) 3.35
Appearance of virus-specific DNA in mammalian cells following transformation by Rous sarcoma virus. J Mol Biol (1973) 3.21
DEAE-dextran: enhancement of cellular transformation induced by avian sarcoma viruses. Virology (1967) 3.20
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
Patterns of viral interference in the avian leukosis and sarcoma complex. Virology (1966) 3.12
Genetically stable reassortment of markers during mixed infection with avian tumor viruses. Virology (1971) 3.05
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology (1971) 3.00
The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A (1998) 2.99
High-molecular-weight RNAs of AKR, NZB, and wild mouse viruses and avian reticuloendotheliosis virus all have similar dimer structures. J Virol (1978) 2.96
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ (2001) 2.85
Temperature sensitive mutants of an avian sarcoma virus. Virology (1969) 2.73
Localization of avian tumor virus group-specific antigen in cell and virus. Virology (1966) 2.70
Immunological relationships among envelope antigens of avian tumor viruses. Virology (1966) 2.67
Avian tumor viruses. Adv Virus Res (1965) 2.58
A virus released by "nonproducing" Rous sarcoma cells. Proc Natl Acad Sci U S A (1967) 2.52
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev (1990) 2.46
RNA of replication-defective strains of Rous sarcoma virus. Proc Natl Acad Sci U S A (1975) 2.37
Avian RNA tumor viruses: mechanism of recombination and complexity of the genome. Cold Spring Harb Symp Quant Biol (1975) 2.37
Properties of mammalian cells transformed by temperature-sensitive mutants of avian sarcoma virus. Cell (1977) 2.36
Distribution of envelope-specific and sarcoma-specific nucleotide sequences from different parents in the RNAs of avian tumor virus recombinants. Proc Natl Acad Sci U S A (1976) 2.32
v-jun encodes a nuclear protein with enhancer binding properties of AP-1. Cell (1988) 2.31
Electron microscope studies of tumor virus RNA. Cold Spring Harb Symp Quant Biol (1975) 2.30
The defectiveness of Mill Hill 2, a carcinoma-inducing avian oncovirus. Virology (1978) 2.26
Occurrence of partial deletion and substitution of the src gene in the RNA genome of avian sarcoma virus. Proc Natl Acad Sci U S A (1977) 2.22
Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. Proc Natl Acad Sci U S A (1979) 2.16
Homologous tyrosine phosphorylation sites in transformation-specific gene products of distinct avian sarcoma viruses. Nature (1981) 2.11
Mapping oligonucleotides of Rous sarcoma virus RNA that segregate with polymerase and group-specific antigen markers in recombinants. Proc Natl Acad Sci U S A (1976) 2.04
Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII. Virology (1981) 2.03
Restitution of fibroblast-transforming ability in src deletion mutants of avian sarcoma virus during animal passage. Virology (1979) 1.93
Effects of genetic cellular resistance on cell transformation and virus replication in chicken hematopoietic cell cultures infected with avian myeloblastosis virus (BAI-A). Virology (1968) 1.88
Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci U S A (1999) 1.81
Presence of avian tumor virus group-specific antigen in nonproducing Rous sarcoma cells of the chicken. Virology (1965) 1.81
Ts pol mutants of avian sarcoma viruses: mapping and demonstration of single cycle recombinants. Virology (1978) 1.74
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem (2000) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene (2001) 1.70
The terminal oligonucleotides of avian tumor virus RNAs are genetically linked. Virology (1977) 1.70
Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci U S A (1999) 1.69
Genome of avian myelocytomatosis virus MC29: analysis by heteroduplex mapping. Proc Natl Acad Sci U S A (1979) 1.68
Envelope classification of avian RNA tumor viruses. Bibl Haematol (1970) 1.67
Characterization of a 105,000 molecular weight gag-related phosphoprotein from cells transformed by the defective avian sarcoma virus PRCII. Virology (1981) 1.67
The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. Proc Natl Acad Sci U S A (1993) 1.67
Isolation of three new avian sarcoma viruses: ASV 9, ASV 17, and ASV 25. Virology (1985) 1.60
The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci U S A (1996) 1.47
RNA tumor viruses of pheasants: characterization of avian leukosis subgroups F and G. Virology (1974) 1.47
A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene (2007) 1.44
Oncogenic signaling of class I PI3K isoforms. Oncogene (2007) 1.43
The avian cellular homolog of the oncogene jun. Oncogene (1988) 1.42
Nuclear translocation of viral Jun but not of cellular Jun is cell cycle dependent. Proc Natl Acad Sci U S A (1992) 1.41
Genetic analysis of the defectiveness in strain MC29 avian leukosis virus. Virology (1978) 1.38
An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proc Natl Acad Sci U S A (1998) 1.37
An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33
Determination of the defective function in two mutants of Rous sarcoma virus. Virology (1974) 1.33
Electron microscopy of chick fibroblasts infected by defective rous sarcoma virus and its helper. J Virol (1967) 1.31
Avian erythroblastosis virus: transformation-specific sequences form a contiguous segment of 3.25 kb located in the middle of the 6-kb genome. Virology (1979) 1.29
Oncogenicity of avian leukosis viruses of different subgroups and of mutants of sarcoma viruses. Infect Immun (1977) 1.29
Conditional lethal mutants of avian sarcoma viruses. I. Physiology of ts 75 and ts 149. Virology (1971) 1.28
The pathogenicity and defectiveness of PRCII: a new type of avian sarcoma virus. Virology (1981) 1.28
The oncogene jun and nuclear signalling. Trends Biochem Sci (1989) 1.26
RNA tumor virus specific sequences in nuclear DNA of several avian species. Virology (1975) 1.26
Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73, and Fujinami viruses. Proc Natl Acad Sci U S A (1981) 1.24
Esh avian sarcoma virus codes for a gag-linked transformation-specific protein with an associated protein kinase activity. Virology (1981) 1.23
The reproductive and cell-transforming capacities of avian sarcoma virus B77: inactivation with UV light. Virology (1970) 1.23
A third class of avian sarcoma viruses, defined by related transformation-specific proteins of Yamaguchi 73 and Esh sarcoma viruses. Proc Natl Acad Sci U S A (1981) 1.22
Cell-free translation of avian erythroblastosis virus RNA yields two specific and distinct proteins with molecular weights of 75,000 and 40,000. Virology (1980) 1.21
PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med (2001) 1.21
A newly isolated avian sarcoma virus, ASV-1, carries the crk oncogene. Oncogene (1989) 1.20
Constitutively active Rheb induces oncogenic transformation. Oncogene (2008) 1.20
Cooperative and antagonistic interactions among RNA tumor viruses. Natl Cancer Inst Monogr (1968) 1.19
Interaction of cellular factors related to the Jun oncoprotein with the promoter of a replication-dependent hamster histone H3.2 gene. Proc Natl Acad Sci U S A (1989) 1.18
Proposal for numbering mutants of avian leukosis and sarcoma viruses. J Virol (1974) 1.17
Mutations in the Jun delta region suggest an inverse correlation between transformation and transcriptional activation. Proc Natl Acad Sci U S A (1992) 1.15
Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell Signal (2000) 1.14
The genomic RNA of avian reticuloendotheliosis virus REV. Virology (1980) 1.14